机构地区:[1]江南大学附属无锡市第五人民医院药剂科,江苏省无锡市214000 [2]江南大学附属无锡市第五人民医院消化科,江苏省无锡市214000
出 处:《实用肝脏病杂志》2022年第2期219-222,共4页Journal of Practical Hepatology
摘 要:目的探讨多烯磷脂酰胆碱联合扶正化瘀片治疗非酒精性脂肪性肝病(NAFLD)患者的疗效及对肝脏超声脂肪变性评分的影响。方法2018年1月~2020年1月我院诊治的NAFLD患者132例,采用随机数字表法分为对照组66例和联合组66例,分别给予多烯磷脂酰胆碱或多烯磷脂酰胆碱联合扶正化瘀片治疗24周。采用ELISA法检测血清肿瘤坏死因子-α(TNF-α)水平,采用化学发光法检测血清高敏C反应蛋白(hs-CRP)和白介素-10(IL-10)水平,采用超声肝脏脂肪变性评分。结果在治疗结束时,联合组血清ALT、AST和GGT水平分别为(39.4±4.1)U/L、(35.8±6.6)U/L和(81.4±10.1)U/L,显著低于对照组[分别为(54.3±5.2)U/L、(50.9±7.4)U/L和(108.8±12.6)U/L,P<0.05];联合组血清TC、TG和LDL-C水平分别为(3.5±1.0)mmol/L、(2.2±0.6)mmol/L和(2.7±0.6)mmol/L,显著低于对照组[分别为(4.2±1.2)mmol/L、(2.9±0.8)mmol/L和(3.4±0.8)mmol/L,P<0.05],而血清HDL-C水平为(1.7±0.6)mmol/L,显著高于对照组[(1.3±0.5)mmol/L,P<0.05];联合组肝脏超声脂肪变性评分和血清TNF-α水平分别为(0.9±0.2)分和(3.5±0.8)ng/L,显著低于对照组[分别为(1.7±0.3)分和(4.2±1.0)ng/L,而血清IL-10水平为(28.9±7.4)ng/L,显著高于对照组(24.1±6.7)ng/L,P<0.05]。结论应用多烯磷脂酰胆碱联合扶正化瘀片治疗NAFLD患者可更好地发挥肝功能改善和降脂效果,改善了肝脏脂肪变性,可能与抑制了炎症反应有关。Objective The purpose of this study was to investigate the efficacy of polyene phosphatidylcholine and Fuzheng Huayu capsule,a herbal medicine,combination in the treatment of patients with non-alcoholic fatty liver diseases(NAFLD)and its effect on hepatic steatosis score(HSSu)by ultrasonography.Methods A total of 132 patients with NAFLD were recruited in our hospital between January 2018 and January 2020,and were randomly divided into control(n=66)and observation group(n=66),receiving orally polyene phosphatidylcholine or polyene phosphatidylcholine and Fuzheng Huayu combination therapy for 24 weeks.Serum tumor necrosis factor-α(TNF-α),high sensitivity C-reactive protein(hs-CRP)and interleukin-10(IL-10)levels were assayed.The hepatic steatosis scores was evaluated by ultrasonography.Serum alanine aminotransferase(ALT),aspartate aminotransferase(AST),gamma glutamine transferase(GGT),serum alkaline phosphatase(ALP),total cholesterol(TC),triglyceride(TG),high-density lipoprotein cholesterol(HDL-C)and low density lipoprotein cholesterol(LDL-c)levels were detected routinely.Results At the end of 24 week observation,serum ALT,AST and GGT levels in the observationgroup were(39.4±4.1)U/L,(35.8±6.6)U/L and(81.4±10.1)U/L,significantly lower than[(54.3±5.2)U/L,(50.9±7.4)U/L and(108.8±12.6)U/L,respectively,P<0.05]in the control;blood TC,TG and LDL-C levels were(3.5±1.0)mmol/L,(2.2±0.6)mmol/L and(2.7±0.6)mmol/L,significantly lower than[(4.2±1.2)mmol/L,(2.9±0.8)mmol/L and(3.4±0.8)mmol/L,respectively,P<0.05],while blood HDL-C level was(1.7±0.6)mmol/L,significantly higher than[(1.3±0.5)mmol/L,P<0.05]in the control group;the hepatic steatosis score and serum TNF-αlevel were(0.9±0.2)and(3.5±0.8)ng/L,significantly lower than[(1.7±0.3)and(4.2±1.0)ng/L,while serum IL-10 level was(28.9±7.4)ng/L,significantly higher than(24.1±6.7)ng/L,P<0.05]in the control.Conclusion The oral administration of polyene phosphatidylcholine and Fuzheng Huayu combination in the treatment of patients with NAFLD could improve liver fun
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...